Financial news API & MCP server

Financial newsfor AI agents.

Stock market news and SEC filing updates, scored for relevance and sentiment. Available through a REST API and MCP server.

10,000+
Articles scanned daily

Crawled and deduplicated across the open web.

6,900+
Sources monitored

Distinct publisher domains scanned in the last 30 days.

<1 in 5
Makes the feed

Only the best clear the relevance floor.

~6 min
SEC filing to feed

Median from EDGAR publication to an enriched, ticker-tagged row.

Top stories

All stories →
M&ANOV 89 / 10

Silver Lake and PIF weigh a roughly $25 billion buyout of Unity

Unity Software was approached in recent weeks by a group including Silver Lake Partners and Saudi Arabia’s Public Investment Fund about taking the company private, according to people familiar with the discussions. The group considered a valuation of about $25 billion before Unity’s latest results, while the company’s market capitalization was roughly $21.5 billion afterward. Unity is working with an investment bank to assess its options, but no agreement has been reached and the terms could change.

$U24 sources · 23 publishers
Delivery

News alerts in Telegram, email, or a webhook.

Set up alerts →
$RVMDHighAI 8/10

105 Hedge Funds Own This Cancer Drug Stock After a Breakthrough — Is Something Bigger Coming?

Revolution Medicines (RVMD) ranked 6th in a list of top healthcare and insurance stocks to buy after the 2026 Democratic midterm sweep, with 105 hedge funds owning it. The company's cancer drug, Rasonque, received US approval and generated $197.6M in net product revenue in Q3 2026. Analysts note potential legislative changes could impact healthcare sector performance.

$RVMDLow

Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug

Revolution Medicines' pancreatic cancer drug, daraxonrasib, received FDA approval. Royalty Pharma, which invested in the drug, estimates peak revenues of $11 billion. Royalty Pharma could earn up to $340 million in royalties. The company has investments in 35 approved drugs, 16 of which are blockbusters. Royalty Pharma offers diversification and a 1.4% dividend yield.

Stock news API with sentiment and relevance scores

The same scored news feed that powers AlphAI is available as a REST API, and as an MCP server for Claude Desktop, Cursor, and any other agent host. Articles arrive enriched and linked to tickers in real time.

  • Real-time + historical news
  • Per-ticker filters and search
  • Relevance-scored 1–10
  • Free tier + paid scale

Dropping it into an existing stack? The Python and n8n quick starts are copy-paste.

curl https://api.alphai.io/api/news/ \
  -H "Authorization: Bearer ${ALPHAI_API_KEY}" \
  -G -d "symbol=NVDA"

# → {
#   "results": [{
#     "original": {
#       "title": "Nvidia export curbs tighten...",
#       "summary": "The White House is expected to...",
#       "time_published": "2026-04-18T14:32:00Z"
#     },
#     "enrichment": {
#       "category": "macro",
#       "tickers": ["NVDA"],
#       "relevance_score": 9
#     }
#   }, ...],
#   "next_cursor": "MjAyNi0wNC0xOFQxNDozMjowMHw0Mg=="
# }

Three plans. One feed.

Free reads the feed and probes the APIs. Paid plans drop the ads and scale up the rate.

Free

$0forever
  • Unlimited articles on the website
  • REST + MCP: 20 / min · 100 / day each, 1 API key
  • Sponsored placements visible
Start for free

Basic

$2.99$7.99/month
  • No ads, unlimited watchlist
  • Daily digest of ticker alerts
  • REST API: 60 / min · 10,000 / day, 1 key
  • MCP server: 60 / min · 10,000 / day
Get started

Pro

$9.99$24.99/month
  • Everything in Basic
  • REST API: 150 / min · 100,000 / day, 5 keys
  • MCP server: 150 / min · 100,000 / day + bulk
Get started

Subscribe now and keep this rate for as long as you stay subscribed. We will not raise it for you.

Don’t want to watch the feed? Follow a ticker and we’ll deliver a daily digest of everything that clears your relevance bar, so you don’t have to check back.

Set up alerts